ClinicalTrials.Veeva

Menu
Unidad de Atencion Medica e Investigacion en Salud (UNAMIS) | Clinical Protocols Department logo

Unidad de Atencion Medica e Investigacion en Salud (UNAMIS) | Clinical Protocols Department

Research site

Site insights

Top conditions

Top treatments

Risankizumab
Ontamalimab
HZN-825
Celecoxib
Doravirine
Afimetoran
Avastin
CC-220
Pregabalin
PF04965842

Data sourced from clinicaltrials.gov

Contact this site

Juan José Rivera Alcocer

Verified by this site

Active trials

6 of 21 total trials

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: Placebo
Drug: HZN-825 QD

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Afimetoran

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

Primary Objectives:1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with...

Invitation-only
Diffuse Cutaneous Systemic Sclerosis
Sclerosis, Systemic
Drug: HZN-825

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 wee...

Enrolling
Human Immunodeficiency Virus (HIV) Infection
Drug: 2 NRTIs
Drug: Doravirine

Trial sponsors

AbbVie logo
Shire logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo
Celgene logo
Merck Sharp & Dohme (MSD) logo
Novavax logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems